REGULATORY

• Respond to Wage Hikes for Medical Workers in FY2024 Reform: Ex-Minister
  September 13, 2023

• Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
  September 13, 2023

• Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
  September 12, 2023

• New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
  September 12, 2023

• New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
  September 12, 2023

• Japan to End Free COVID Vaccine Program in March, Weighs NIP Inclusion
  September 11, 2023

• Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
  September 11, 2023

• PMDA Reviewing Safety Risks for G-CSF Agents, Yervoy and More
  September 11, 2023

• MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
  September 11, 2023

• Japan Mulling Once-a-Year COVID Booster for Elderly in FY2024
  September 8, 2023

• MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
  September 8, 2023

• LDP Lawmakers Deplore Reported GMP Issues at Sawai
  September 8, 2023

• MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
  September 7, 2023

• Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
  September 7, 2023

• Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
  September 7, 2023

• Japan Unveils 2nd Package Strategy for SaMD
  September 7, 2023

• Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
  September 6, 2023

• Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
  September 6, 2023

• MHLW to Launch Working Group on Drug Supply Info on Sept. 7
  September 5, 2023

• 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
  September 5, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 78
• 79
• 80
• 81
• 82
• 83
• 84
• 85
• 86
• …
• Next ›
• 最終 »